- Meeting abstract
- Open access
- Published:
Interferon-alpha and angiogenic dysregulation in pregnant lupus patients destined for preeclampsia
Arthritis Research & Therapy volume 16, Article number: A28 (2014)
Background
Pregnant patients with SLE are at increased risk of placental insufficiency and preeclampsia, disorders associated with angiogenic factor imbalance. IFNα, a critical element in SLE pathogenesis, is a potent antiangiogenic factor. In a case-control longitudinal study of lupus pregnancies from PROMISSE (Predictors of Pregnancy Outcome: Biomarkers In Antiphospholipid Antibody Syndrome and Systemic Lupus Erythematosus), we investigated whether elevated IFNα early in pregnancy might be associated with poor pregnancy outcomes.
Methods
Each of 28 SLE patients with poor pregnancy outcome was matched to an SLE patient with an uncomplicated pregnancy and to a pregnant healthy control. Serum samples obtained monthly through pregnancy were assayed for IFNα activity using a reporter cell assay, and for antiangiogenic factor, sFlt1, and proangiogenic factor, placenta growth factor (PlGF). Human umbilical vein endothelial cells (HUVEC) were cultured in the presence of IFNα and/or sFlt1, and gene expression assessed by q-RT PCR. The effect of IFNα and sFlt1 on endothelial-trophoblast interactions was assessed in an in vitro model of spiral artery transformation in which the capacity of human first trimester extravillous trophoblasts to stabilize endometrial endothelial cell tube structures is measured.
Results
Compared with SLE patients with uncomplicated pregnancies, those with preeclampsia had increased IFNα before clinical symptoms. Nonautoimmune patients destined for preeclampsia did not have increased IFNα. In SLE patients with low IFNα, marked angiogenic imbalance (higher sFlt1, lower PlGF and higher sFlt1/PLGF ratios) precedes maternal manifestations of preeclampsia, whereas in SLE with high IFNα, preeclampsia occurs without evidence of systemic angiogenic imbalance. To investigate this result, we treated HUVEC with exogenous sFlt1 and IFNα. Treatment with sFlt1 induced the expression of sFlt1 mRNA, and IFNα dramatically amplified the endothelial response to sFlt1, leading to a local positive feedback loop. Furthermore, in an in vitro model of spiral artery transformation, only IFNα and sFlt1 together disrupted the ability of trophoblast cells to remodel endothelial tube structures.
Conclusions
Our studies identify a new mechanism by which IFNα induces an antiangiogenic milieu in the vasculature leading to inadequate spiral artery remodeling and poor placentation early in pregnancy and maternal endothelial dysfunction presenting as preeclampsia later in pregnancy. They suggest that elevated IFNα may contribute to the pathogenesis of preeclampsia in some pregnant women with SLE.
Acknowledgements
Supported by NIAMS [http://ClinicalTrials.gov:NCT00198068].
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made.
The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.
To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Andrade, D., Kim, M., Blanco, L.P. et al. Interferon-alpha and angiogenic dysregulation in pregnant lupus patients destined for preeclampsia. Arthritis Res Ther 16 (Suppl 1), A28 (2014). https://doiorg.publicaciones.saludcastillayleon.es/10.1186/ar4644
Published:
DOI: https://doiorg.publicaciones.saludcastillayleon.es/10.1186/ar4644